Keiji Nogami

Professor
Nara Medical University, Nara, Japan

Presentation(s):

• LB 01.2 - Concizumab Prophylaxis in Patients With Haemophilia A or B With Inhibitors: Efficacy and Safety Results From the Primary Analysis of the Phase 3 explorer7 Trial

  Sunday, July 10, 2022
  3:00 PM – 3:15 PM

• LB 01.4 - Efficacy, Safety, and Pharmacokinetics of Once-Weekly Efanesoctocog Alfa (BIVV001) Prophylaxis in Previously Treated Patients With Severe Hemophilia A: Results From the Phase 3 XTEND-1 Study

  Sunday, July 10, 2022
  3:30 PM – 3:45 PM

• VPB0171 - The effect of anti-coagulant agents against in vitro hemophilia A plasma coagulation and fibrinolysis potential in the presence of emicizumab

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• VPB0207 - Factor VIII K1813A has high affinity for activated factor IX and enhances global coagulation function

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• VPB0208 - Coagulant potential of emicizumab in child hemophilia A patients

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• OC 40.2 - Efficacy, Safety, and Pharmacokinetics of Emicizumab Prophylaxis in Patients with Acquired Hemophilia A: Primary Analysis Results from a Phase III Study (AGEHA)

  Monday, July 11, 2022
  3:00 PM – 3:15 PM

• VPB0841 - A case of hematidrosis complicated with von Willebrand disease

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• VPB1047 - The FV-A2086D mutation results in impaired anticoagulant function.

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM